Autoimmune Disease
Medical Education
B.A.: Kansas University, Lawrence, Kansas, 1965
Medical Degree: Kansas University, Lawrence, Kansas, 1969
Residency: Internal Medicine, Massachusetts General Hospital, Nat Institutes of Health, Boston, Massachusetts, 1972
Fellowship: Allergy & Clinical Immunology, National Institutes of Health, Boston, Massachusetts, 1974
Fellowship: Rheumatology, Massachusetts General Hospital, Nat Institutes of Health, Boston, Massachusetts, 1974
Honors and Awards
Listed in Best Doctors in America, 2003-2013 (Best Doctors, Inc.)
Innovator in Arthritis Care Award, Arthritis Foundation, Eastern Missouri Chapter, 1998
Paul Klemperer Medalist, New York Academy of Medicine, 1996
Disclosure of Financial Interests with IndustryWashington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.
Dr. John Patterson Atkinson reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
| Company | Royalties Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product. | Equity Equity: Equity is an ownership interest in a company. Faculty members may be paid for their service to a company in stock or the option to obtain stock. | Consulting &
Advisory Boards Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board. | Speaker Fees Speaker Fees: Companies may pay faculty to speak to professional audiences about their products. |
| Compliment | | Yes | $1,000-$10,000 | |
To learn more about Washington University's policies on collaborations with industry,
click here.
Books and Book Chapters
Bala Subramanian V, Liszewski MK and Atkinson JP: The Complement System and Autoimmunity. In: Textbook of
the Autoimmune Diseases. R Lahita, N Chiorazzi, W Reeves (eds) Lippincott, Williams & Wilkins, Philadelphia, PA 2000; 117-135
Liszewski MK, Bala Subramanian VG and Atkinson JP: Complement Inhibitors as Therapeutic Agents. In: Clinical Immunology Newsletter. MRG O'Gorman (ed). Elsevier Science, Inc, New York, NY 1998; 17:168-173
Liszewski MK and Atkinson JP: Regulatory Proteins of Complement. In: The Human Complement System in Health and Disease. J Volanakis and M Frank (eds). Marcel Dekker, Inc, New York 1998; 149-166
Selected Journal Articles
Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome.
Mol Immunol. In press
Spitzer D, Wu X, Ma X, Xu L, Ponder KP, Atkinson JP. Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy. J Immunol 2006; 15;177(8):4953-6
Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP.
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006 Jul; 17(7):2017-25
Atkinson JP. C5a and Fcgamma receptors: a mutual admiration society.
J Clin Invest 2006 Feb; 116(2):304-6
Atkinson JP, Liszewski MK, Richards A, Kavanagh D, Moulton EA. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann N Y Acad Sci. 2005 Nov; 1056:144-52
Gill DB, Spitzer D, Koomey M, Heuser JE, Atkinson JP. Release of host-derived membrane vesicles following pilus-mediated adhesion of Neisseria gonorrhoeae. Cell Microbiol 2005 Nov; 7(11):1672-83
Price JD, Schaumburg J, Sandin C, Atkinson JP, Lindahl G, Kemper C.
Induction of a regulatory phenotype in human CD4+ T cells by streptococcal M protein. J Immunol. 2005 Jul 15; 175(2):677-84
Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells.
Blood. 2004 Nov 1; 104(9):2840-8
Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol. 2004 Apr; 113(4):585-93
Riley RC, Kemper C, Leung M, Atkinson JP. Characterization of human membrane cofactor protein (MCP; CD46) on spermatozoa. Mol Reprod Dev 2002; Aug;62(4):534-46
Barilla-LaBarca ML, Gioffre D, Zanichelli A, Cicardi M, Atkinson JP. Acquired C1 esterase inhibitor deficiency in two patients presenting with a lupus-like syndrome and anticardiolipin antibodies. Arthritis Rheum 2002; Apr 15;47(2):223-6
Kallstrom H, Blackmer-Gill DJ, Albiger B, Liszewski MK, Atkinson JP and Jonsson A-B. Attachment of Neisseria gonorrhoeae to the cellular pilus receptor CD46: identification of domains important for bacterial adherence. Cellular Microbiology 2001 3:133-143
For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr John P. Atkinson